Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Rosenblit, Paul D.

doi:10.1186/s12933-016-0412-7

Cited by 58 publications

(51 citation statements)

References 150 publications

(189 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, we noted an increase in the lipid components such as LDL that are susceptible to peroxidation. Interestingly, we found that T1DM patients had higher levels of HDL compared to controls, which is inconsistent with results of previous studies (15). Moreover, we observed that HDL level was significantly higher in T2DM patients with no history of statin therapy.…”

Section: Discussioncontrasting

confidence: 99%

Evaluation of Fasting Blood Sugar and Lipid Profile in Patients with Type 1 and Type 2 Diabetes and Normoglycemic Individuals in Gorgan, Northeastern

Sarhadi

Fakhreddin-nejad

Rajabi

et al. 2019

jcbr

View full text Add to dashboard Cite

Background and objectives:Diabetes mellitus is a major public health issue worldwide. Poorly managed type 1 and type 2 diabetics are at risk of developing several complications, including cardiovascular disease. Therefore, monitoring lipid profile and glycemic control in such patients are of great importance for reducing the risk of developing diabetic complications. In this study, we measured the level of fasting blood sugar (FBS) and lipid profile components in patients with either type 1 or type 2 diabetes and non-diabetic individuals. Methods: This cross-sectional case-control study was conducted on 50 type 1 diabetics, 50 type 2 diabetics and 50 normoglycemic individuals (controls). All subjects were matched in terms of age and gender. Serum level of FBS, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) was measured using commercial kits. Statistical analysis was performed using SPSS software (version 16) at significance level of 0.05. Results: The levels of FBS, TC, TG, LDL and HDL were higher in both case groups compared to the controls. The value of these variables (except for TC) was significantly higher in patients with type 1 diabetes than in patients with type 2 diabetes. Conclusion: Our results show that patients with type 2 diabetes have lower levels of HDL compared to T1DM patients, which might increase the risk of developing cardiovascular complications in these patients.

show abstract

Section: Discussioncontrasting

confidence: 99%

Evaluation of Fasting Blood Sugar and Lipid Profile in Patients with Type 1 and Type 2 Diabetes and Normoglycemic Individuals in Gorgan, Northeastern

Sarhadi

Fakhreddin-nejad

Rajabi

et al. 2019

jcbr

View full text Add to dashboard Cite

show abstract

“…Briefly, various treatments have been shown to have modest but positive lipid effects, including metformin, GLP1 receptor agonists, DPP-4 inhibitors, alfa-glucosidase inhibitors, colesevelam, and insulin [62•, 63, 64, 65, 66, 67, 68, 69]. Pioglitazone also has TG-lowering effects while rosiglitazone can increase TG levels [70].…”

Section: Current Treatment Guidelinesmentioning

confidence: 99%

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes

et al. 2017

View full text Add to dashboard Cite

Purpose of Review Current preventive and treatment guidelines for type 2 diabetes have failed to decrease the incidence of comorbidities, such as dyslipidemia and ultimately heart disease. The goal of this review is to describe the physiological and metabolic lipid alterations that develop in patients with type 2 diabetes mellitus. Questions addressed include the differences in lipid and lipoprotein metabolism that characterize the dyslipidemia of insulin resistance and type 2 diabetes mellitus. We also examine the relevance of the new AHA/ADA treatment guidelines to dyslipidemic individuals. Recent Findings In this review, we provide an update on the pathophysiology of diabetic dyslipidemia, including the role of several apolipoproteins such as apoC-III. We also point to new studies and new agents for the treatment of individuals with type 2 diabetes mellitus who need lipid therapies. Summary Type 2 diabetes mellitus causes cardiovascular disease via several pathways, including dyslipidemia characterized by increased plasma levels of apoB-lipoproteins and triglycerides, and low plasma concentrations of HDL cholesterol. Treatments to normalize the dyslipidemia and reduce the risk for cardiovascular events include the following: lifestyle and medication, particularly statins, and if necessary, ezetimibe, to significantly lower LDL cholesterol. Other treatments, more focused on triglycerides and HDL cholesterol, are less well supported by randomized clinical trials and should be used on an individual basis. Newer agents, particularly the PCSK9 inhibitors, show a great promise for even greater lowering of LDL cholesterol, but we await the results of ongoing clinical trials.

show abstract

“…Diabetic dyslipidemia, which is characterized by raised triglycerides and low HDL cholesterol levels, is one contributor to the high cardiovascular risk of T2D [18]. Several medications commonly used in T2D patients may affect the lipid profile [19] and a therapeutic increase in HDL cholesterol may explain, at least in part, cardiovascular protection by SGLT-2i.…”

Section: Introductionmentioning

confidence: 99%

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

Fadini

Bonora

Zatti

et al. 2017

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundSodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects HDL function in a randomized placebo-controlled trial.MethodsThirty-three type 2 diabetic patients were randomized to receive dapagliflozin 10 mg or placebo for 12 weeks on top of their glucose lowering medications. The primary end-point was the change in cholesterol efflux capacity (CEC) from macrophages at study end versus baseline. Secondary endpoints were changes in: distribution of HDL subfractions, lipid profile, activity of enzymes that mediate HDL antioxidant properties (PON1 and ARE) and cholesterol metabolism (CETP), HbA1c, body weight and composition.ResultsThirty-one patients completed the study, n = 16 in the placebo group and n = 15 in the dapagliflozin group. Patients randomized to dapagliflozin were older and had lower adiposity indexes, although these differences disappeared after correction for multiple testing. Therapy with dapagliflozin reduced HbA1c by 0.9% and body weight by 3.1 kg, mainly attributable to reduction of body water and lean mass. As compared to placebo, dapagliflozin reduced CEC (−6.7 ± 2.4 versus 0.3 ± 1.8%; p = 0.043), but this effect was no longer significant after adjusting for age and BMI. No change was detected in HDL cholesterol, HDL subfractions, activity of PON1, ARE, and CETP.ConclusionsDespite improvements in glucose control and reduction in body weight, therapy with dapagliflozin exerted no significant effect on HDL cholesterol levels and HDL functionality. Trial registration EudraCT 2014-004270-42; NCT02327039Electronic supplementary materialThe online version of this article (doi:10.1186/s12933-017-0529-3) contains supplementary material, which is available to authorized users.

show abstract

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Cited by 58 publications

References 150 publications

Evaluation of Fasting Blood Sugar and Lipid Profile in Patients with Type 1 and Type 2 Diabetes and Normoglycemic Individuals in Gorgan, Northeastern

Evaluation of Fasting Blood Sugar and Lipid Profile in Patients with Type 1 and Type 2 Diabetes and Normoglycemic Individuals in Gorgan, Northeastern

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

Contact Info

Product

Resources

About